Real-World Evidence of Angiotensin Receptor-Neprilysin Inhibitor in Patients with Heart Failure (REVIEW-HF)

Real-World Evidence of Angiotensin Receptor-Neprilysin Inhibitor in Patients with Heart Failure (REVIEW-HF) - REVIEW-HF

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047636

Enrollment

1000

Registered

2022-05-01

Start date

2022-01-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with the initiation of treatment with ARNI from June 29, 2020 to August 31, 2021.

Exclusion criteria

Exclusion criteria: 1. Under 20 years old. 2. Refusal to participate. 3. The cases considered inappropriate.

Design outcomes

Primary

Measure	Time frame
Adverse events (symptomatic/asymptomatic hypotension, hyperkalemia, angioedema, discontinuation of ARNI)	—

Countries

Japan

Contacts

Public ContactShingo Matsumoto

Toho University Faculty of Medicine Department of Cardiology

shingomatsumoto0606@gmail.com+81337624151

Outcome results